Following Patients With Skin Conditions Such as Vitiligo, Atopic Dermatitis and Alopecia Areata
Collects real-world treatment results from people with skin diseases and their doctors.
Plain-language title generated from the registry record
Registry title: An Observational Study of Patients With Dermatologic Disease
Key facts
- Where
- New York, United StatesSee the site
Where in United States
- Greenwich Village DermatologyNew York, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Target PharmaSolutions, Inc.
- Trial code
- NCT07748169
- Record updated
- 10 September 2026
- Original description
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.Read full original descriptionShow less
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.
Inclusion: Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants; Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface.
Exclusion: Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.